Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)

NCT01550224 is registered in ClinicalTrials.gov with Steven E. Coutre as lead sponsor.

NCT NCT01550224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01550224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Steven E. Coutre
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2013
Completion date
November 17, 2014
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with 11q23-abnormality in relapse